HF/Transplantation News

CHICAGO — Treatment with the heart failure medication sacubitril/valsartan was associated with a lower risk for chemotherapy-related heart damage among high-risk patients with cancer, according to preliminary results of the SARAH trial.

CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported.

CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.

CHICAGO — Catheter ablation improved outcomes compared with antiarrhythmic drug therapy in patients with ventricular tachycardia and ischemic cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions.

CHICAGO — A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin reduced transthyretin levels in patients with cardiac amyloidosis, researchers reported at the American Heart Association Scientific Sessions.

CHICAGO — In adults with HF with preserved ejection fraction and obesity, treatment with tirzepatide cut risk for CV death or worsening HF by 38% compared with placebo, with a parallel improvement in health status and exercise tolerance.

Editor’s Note: This is part three of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .

Editor’s Note: This is part two of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy.

Editor’s Note: This is part one of a three-part Healio Exclusive series on the development and use of AI to improve clinical outcomes in cardiovascular medicine and considerations for regulatory labeling and patient privacy .